GoodRx Holdings (GDRX) Depreciation & Amortization (CF) (2019 - 2026)

GoodRx Holdings has disclosed Depreciation & Amortization (CF) across 8 years of filings, most recently posting $22.3 million for Q2 2026.

• In Q2 2026, Depreciation & Amortization (CF) rose 12.87% year-over-year to $22.3 million; the TTM figure through Jun 2026 stood at $88.6 million (up 14.71% YoY), while the FY2025 annual figure was $85.2 million, up 22.55% from the prior year.
• Depreciation & Amortization (CF) came in at $22.3 million for Q2 2026 at GoodRx Holdings, up from $21.8 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $43.6 million in Q4 2023 to a low of $11.4 million in Q1 2022.
• Average Depreciation & Amortization (CF) over 5 years is $20.0 million, with a median of $18.3 million recorded in 2024.
• Year-over-year, Depreciation & Amortization (CF) jumped 180.74% in 2023 and tumbled 56.21% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $15.5 million in 2022, then jumped by 180.74% to $43.6 million in 2023, then plunged by 56.21% to $19.1 million in 2024, then rose by 21.21% to $23.1 million in 2025, then decreased by 3.79% to $22.3 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $22.3 million in Q2 2026, $21.8 million in Q1 2026, and $23.1 million in Q4 2025.